Bristol-Myers Squibb (BMY) said late Friday its Sotyktu inhibitor has received approval from the US Food and Drug Administration to treat adults with active psoriatic arthritis.

The company said that the approval is based on results from its POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of a 6 mg once-daily dose of Sotyktu in patients with active psoriatic arthritis.

In both trials, treatment with Sotyktu met its primary endpoint and key secondary endpoints, the company said.